- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: YM178 Oral Controlled Absorption System (OCAS)
Total 260253 results
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics of YM178Netherlands
-
Astellas Pharma IncCompletedHealthy Subjects | Bioavailability | Pharmacokinetics of MirabegronNetherlands
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics of YM178United States
-
Astellas Pharma China, Inc.CompletedHealthy Chinese VolunteersChina
-
Astellas Pharma Europe B.V.Completed
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedPharmacokinetics of YM178United States
-
EMSRecruitingBenign Prostatic Hyperplasia | Erectile DysfunctionBrazil
-
Boehringer IngelheimCompleted
-
Astellas Scientific & Medical Affairs, Inc.CompletedUrologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Canada
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder Diseases | Urinary Bladder OveractiveUnited States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
-
Astellas Pharma IncCompletedHealthy Subjects | Plasma Concentration of MirabegronJapan
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Neurogenic Detrusor OveractivityDenmark, Poland
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Australia
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic ImpairmentSlovakia
-
Astellas Pharma IncCompletedHealthy SubjectsUnited States
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacodynamics of MirabegronFrance
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Taiwan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedHealthy | Pharmacokinetics of MirabegronUnited States
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic DiseasesBelgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics of MirabegronNetherlands
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of MirabegronFrance
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of MirabegronFrance
-
Astellas Pharma Global Development, Inc.TerminatedPharmacokinetics of Mirabegron | Overactive Bladder (OAB)Korea, Republic of, Russian Federation, Turkey
-
Astellas Pharma Europe B.V.CompletedUrologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and SymptomsBelarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveChina, Taiwan, India, Korea, Republic of
-
Astellas Pharma IncCompleted
-
Astellas Pharma Europe B.V.Completed
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics | CardiovascularUnited Kingdom
-
Astellas Pharma IncCompletedPost-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of TolterodineHealthy | Pharmacokinetics of Mirabegron and TolterodineJapan
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of MirabegronFrance
-
Astellas Pharma IncCompletedHealthy Volunteer | Pharmacokinetics of YM178Japan
-
Astellas Pharma IncCompletedOveractive Bladder | PharmacokineticsFrance
-
Astellas Pharma Europe B.V.Completed
-
Astellas Pharma Europe B.V.CompletedNeurogenic Detrusor OveractivityBelgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urgency Incontinence | Urinary Bladder OveractiveCzechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
-
Astellas Pharma Europe B.V.CompletedOveractive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic DiseasesUnited States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
-
Astellas Pharma Europe Ltd.CompletedUrologic Diseases | Urinary Bladder, Overactive | Urinary Bladder DiseasesGreece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveJapan
-
Astellas Pharma IncCompletedOveractive Bladder | Cardiovascular DiseaseJapan
-
Astellas Pharma IncCompleted
-
Astellas Pharma IncCompletedIntraocular PressureUnited States
-
Astellas Pharma IncAstellas Pharma Taiwan, Inc.CompletedHealthy Volunteer | Pharmacokinetics of YM178Taiwan
-
Astellas Pharma Global Development, Inc.RecruitingNeurogenic Detrusor OveractivityPhilippines, Turkey, Belgium, Denmark
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada